<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17512" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Medication-Overuse Headache</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fischer</surname>
            <given-names>Michelle A.</given-names>
          </name>
          <aff>Penn State Hershey Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jan</surname>
            <given-names>Arif</given-names>
          </name>
          <aff>Drexel University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michelle Fischer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arif Jan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17512.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Medication-overuse headaches (MOH), also known as analgesic rebound headaches, drug-induced headaches, or medication-misuse headaches, are a common neurologic disorder that results in enormous disability and suffering and plays a significant role in the transformation from episodic to chronic headache disorders. These headaches typically develop in patients with established primary headache disorders like migraine or tension-type headaches who overuse medication in an attempt to alleviate the symptoms of their primary headache. An unfortunate cycle of medication overuse results in increased headache frequency, whereby the medication indicated for the treatment of the primary headache becomes the cause of headaches. Patients prone to headaches who take analgesics for other conditions can also develop MOH. This activity reviews the presentation, evaluation, and management of medication-overuse headaches and highlights the role of an interprofessional team approach to the care of affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the medications typically associated with medication-overuse headaches.</p></list-item><list-item><p>Describe the exam findings typically seen in patients with medication-overuse headaches.</p></list-item><list-item><p>Explain the management considerations for medication-overuse headaches.</p></list-item><list-item><p>Discuss the modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by medication-overuse headaches.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17512&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17512">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17512.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><bold>Medication-overuse headache (MOH)</bold> is a common neurologic disorder with enormous disability and suffering and plays a significant role in the transformation&#x000a0;from episodic to chronic headache disorders. Multiple terms have been used to describe MOH, such as analgesic rebound headache, drug-induced headache, or medication-misuse headache. Patients with established primary headache disorders like migraine or tension-type headaches overuse medication for their acute headaches and inadvertently increase the frequency and intensity of their headaches. In this manner, a vicious cycle of further drug consumption and increased headache frequency develops, transforming the treatment for their headache to the actual cause of their disease (MOH). Patients prone to headaches who take analgesics for other conditions can also develop MOH.<xref ref-type="bibr" rid="article-17512.r1">[1]</xref><xref ref-type="bibr" rid="article-17512.r2">[2]</xref></p>
        <p>Recognition of MOH was as early as in the 1930s when physicians&#x000a0;observed prolongation of headaches associated with ergotamine-overuse.<xref ref-type="bibr" rid="article-17512.r3">[3]</xref> In the 1970s and 1980s, physicians observed its association with analgesics such as barbiturates, codeine, and combination analgesics as well and also noticed a reduction in headache frequency with stopping drugs. For a short time, it was referred to as transformed or&#x000a0;<italic toggle="yes">evolutive migraine</italic>.<xref ref-type="bibr" rid="article-17512.r4">[4]</xref> The first edition of the International Classification of Headache Disorders (ICHD) in 1988 first defined the disorder calling it a drug-induced headache that was a &#x0201c;headache induced by chronic substance use or exposure.&#x0201d;<xref ref-type="bibr" rid="article-17512.r5">[5]</xref> MOH was first introduced in the second edition of ICHD (2004) with multiple subtypes dependent on offending medicine, such as ergotamines, triptans, opioids, etc.<xref ref-type="bibr" rid="article-17512.r6">[6]</xref></p>
      </sec>
      <sec id="article-17512.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Medication overuse headache is classified as a secondary headache or chronic headache syndrome in the latest version of ICHD-3 (2018) under subsection 8.2&#x000a0;as a chronic headache disorder secondary to a pre-existing headache syndrome.<xref ref-type="bibr" rid="article-17512.r7">[7]</xref> The specific subtype of MOH is dependent upon&#x000a0;the medicine involved. Overarching criteria are that (1) a headache is occurring on greater than or equal to 15 days per month for a patient with a pre-existing headache disorder and (2) regular medication overuse for greater than three months of one or more drugs that can be taken for acute and/or symptomatic treatment of a headache and (3) Not better accounted for by another ICHD-3 diagnosis. If multiple drugs are overused, all applicable/multiple codes should be used. There are no clinical characteristics defined as the headache typically resembles the pre-existing headache syndrome. The general rule is that the MOH resolves upon cessation of the medication. In this manner, two diagnoses are made, first, the primary headache syndrome, and second the MOH. It is no longer a requirement for the diagnosis that the headache pattern returns to the previous within two months of stopping the offending drug.&#x000a0;</p>
        <p>As the name implies, chronic medication overuse is the most significant risk factor for the development of MOH, with each class of analgesics carrying a different risk profile.&#x000a0; The risk from lowest to highest is: triptans/ergotamine, single analgesic agents (NSAIDs, acetaminophen), and combination analgesics containing opiates or barbiturates. There have been observations that combination analgesics, particularly those containing opioids and/or barbiturates, have a two-fold increase in relative risk for MOH.&#x000a0;</p>
        <p>Some studies suggest that NSAIDs may have a protective effect from MOH in patients with ten headache days or less per month.<xref ref-type="bibr" rid="article-17512.r8">[8]</xref></p>
      </sec>
      <sec id="article-17512.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Medication overuse headache has a true prevalence that is unknown, partly resulting from various changes in diagnostic criteria, but estimates are in the range of 0.5 to 2.6% in the general population. Higher rates have been reported in Russia (7.6%) and Iran (4.6%), places where it is felt that medication overuse is more prevalent.<xref ref-type="bibr" rid="article-17512.r9">[9]</xref>&#x000a0;In some studies from specialized headache centers, the prevalence of MOH in patients with chronic daily headaches has been reported anywhere from 11 to 70%, much higher than the general population. In approximately 80% of MOH patients,&#x000a0;migraine is the underlying primary headache disorder, with the overwhelming remaining having tension-type or post-traumatic headaches. MOH most commonly affects those aged 30 to 50 years with a female to male predominance of 3 to 4 to 1. Interestingly enough, between 21 and 52% of pediatric patients and 35% of the elderly over the age of 64 met the criteria for MOH. Some studies in Europe have reported increased prevalence in first-generation migrants, and the feeling was that a potential explanation for this was multi-factorial but likely included socioeconomic class, genetic predisposition, and cultural reasons. As MOH is a worldwide problem, experts surmise that economic, psychological, and physical disability all factor into the etiology of this disease. In 2016 Global Burden of Disease (GBD) listed migraine as the second largest cause of disability, likely because MOH was considered an emanation of migraine and tension headache.<xref ref-type="bibr" rid="article-17512.r10">[10]</xref></p>
        <p>
<bold>Main Risk Factors for MOH with Odds Ratio (OR):</bold>
<xref ref-type="bibr" rid="article-17512.r11">[11]</xref>
<xref ref-type="bibr" rid="article-17512.r12">[12]</xref>
<xref ref-type="bibr" rid="article-17512.r13">[13]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Demographic
<list list-type="bullet"><list-item><p>Age (less than 50 years)--1.8</p></list-item><list-item><p>Female--1.9</p></list-item><list-item><p>Low educational level--1.9</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Self-reported complaints
<list list-type="bullet"><list-item><p>Chronic musculoskeletal complaints--1.9</p></list-item><list-item><p>Gastrointestinal complaints--1.6</p></list-item><list-item><p>Anxiety or depression--4.7</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Lifestyle
<list list-type="bullet"><list-item><p>Smoking--1.8</p></list-item><list-item><p>Physical inactivity--2.7</p></list-item><list-item><p>Metabolic syndrome--5.3</p></list-item><list-item><p>High daily caffeine intake (greater than 540mg versus less than 240mg)--1.4</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Medication
<list list-type="bullet"><list-item><p>Tranquilizers--5.2</p></list-item><list-item><p>Aspirin--0.5</p></list-item><list-item><p>Ibuprofen--0.7</p></list-item><list-item><p>Opioids--2.3</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Of those patients with MOH, dependency-like behavior presented more often in those who overuse opioids and triptans than aspirin or ibuprofen. MOH can be associated with the substance-related disorder spectrum as it is believed they share common neurobiological pathways.<xref ref-type="bibr" rid="article-17512.r14">[14]</xref> Data like these support a biological predisposition as another significant risk factor for MOH. Of all headache types, migraine is the one most commonly associated with MOH and occurs in approximately 80% of patients.<xref ref-type="bibr" rid="article-17512.r15">[15]</xref> Patients with higher headache frequency at baseline are also at higher risk for MOH. It is unknown if the high headache frequency leads to more drug consumption and thus MOH or if patients with higher frequency attacks are more prone to MOH. Another study found a threefold risk of MOH if there is a family history of MOH or substance abuse (drug or alcohol).<xref ref-type="bibr" rid="article-17512.r16">[16]</xref> Several trials have demonstrated that frequent and often multiple psychiatric mood disorders such as anxiety and depression exist in patients with MOH.<xref ref-type="bibr" rid="article-17512.r17">[17]</xref> Some&#x000a0;trials interestingly found that 40% of MOH patients actually met the criteria for depression and upwards of 58% for anxiety.<xref ref-type="bibr" rid="article-17512.r18">[18]</xref> It remains unclear if psychiatric comorbidities are risk factors or just the consequences of MOH. The 2011 Hagen longitudinal study found that patients with a tension-type headache had the highest incidence of psychiatric comorbidities. Another study found patients with MOH have a higher susceptibility to drug dependency and obsessive-compulsive disorder (OCD).<xref ref-type="bibr" rid="article-17512.r16">[16]</xref></p>
        <p>In general, the following medicines can cause medication overuse headache, listed in highest to lowest incidence:</p>
        <list list-type="bullet">
          <list-item>
            <p>Opioids, butalbital-containing combination analgesics, and acetaminophen-aspirin-caffeine&#x000a0;combinations<xref ref-type="bibr" rid="article-17512.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Triptans</p>
          </list-item>
          <list-item>
            <p>NSAIDs</p>
          </list-item>
          <list-item>
            <p>Calcitonin gene-related peptide antagonists</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17512.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of MOH is not well understood, but studies have demonstrated that central sensitization likely plays a major role.<xref ref-type="bibr" rid="article-17512.r20">[20]</xref>&#x000a0;Since patients with migraines or tension-like headaches are prone to&#x000a0;developing MOH, the theory is that similar&#x000a0;physiological mechanisms may be involved. The condition exhibits both functional and structural changes in the central nervous system (CNS), particularly the hippocampal periaqueductal gray area, posterior cingulate cortex thalamus, cerebellum, and orbitofrontal cortex (OFC), and the mesocorticolimbic reward system.<xref ref-type="bibr" rid="article-17512.r21">[21]</xref><xref ref-type="bibr" rid="article-17512.r22">[22]</xref>&#x000a0;Also found were changes in the serotonergic neuromodulatory system, upregulation of vasoactive and pro-inflammatory mediators, increased susceptibility to cortical spreading depression, central sensitization, and an increase in nociceptive sensory fields.<xref ref-type="bibr" rid="article-17512.r23">[23]</xref>&#x000a0;Some studies have theorized a potential genetic risk as to the etiology of the development of MOH. One such model is the renin-angiotensin system, known to have an active role in regulating neural plasticity.<xref ref-type="bibr" rid="article-17512.r24">[24]</xref></p>
        <p>The thinking is that the insertion/deletion polymorphism in the gene that encodes an angiotensin-converting enzyme (ACE) increases an individual&#x02019;s susceptibility to MOH. ACE is a key enzyme in regulating blood pressure, but in the brain, it interacts with monoaminergic synaptic transmission, thereby contributing to dependence behavior. ACE polymorphisms seen in MOH patients have been demonstrated to influence sensitization and habituation patterns. Other potential polymorphisms are a brain-derived neurotrophic factor (BDNF), catechol-O-methyltransferase (COMT), and serotonin transporter (SERT).<xref ref-type="bibr" rid="article-17512.r25">[25]</xref><xref ref-type="bibr" rid="article-17512.r26">[26]</xref><xref ref-type="bibr" rid="article-17512.r27">[27]</xref>&#x000a0;All of these lead to disturbances in the normal brain pathway neurotransmitters making patients more susceptible to dependence, behavioral disorders, substance abuse, pain disorders, and several neuropsychiatric disorders.</p>
        <p>Animal studies have also demonstrated that pain medications alone can cause altered neurotransmitter metabolism, especially serotoninergic and endocannabinoid systems.<xref ref-type="bibr" rid="article-17512.r28">[28]</xref> Several human studies have shown hypersensitization and hyperresponsiveness of the cerebral cortex, suggesting that the brain of those suffering from MOH are &#x0201c;locked&#x0201d; in a pre-excitation state.&#x000a0; In fact, all MOH patients exhibited increased somatosensory evoked potential (SEP) amplitude after stimulation, as well as a lack of habituation after further stimulation.<xref ref-type="bibr" rid="article-17512.r29">[29]</xref> After drug discontinuation, a slow progression back to normal sensory processing was observed in most patients and within most areas of the brain. The primary force leading to MOH-related structural and functional properties of the brain seems to be prolonged exposure to pain medications. All pain medications can cause MOH, but some drug classes can cause it faster or with shorter overuse. Therefore it is believed from evidence from multiple studies that MOH causes changes in the central nervous system, specifically in pain processing and dependence networks, sensitization, and receptor density, all of which help to explain the clinical features of the disease.</p>
      </sec>
      <sec id="article-17512.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>As always, detailed history with particular emphasis on evaluating headaches is essential. Equally important is the detailed medication history and history of substance abuse. To be considered for a diagnosis of MOH, a patient must have a headache for 15 or more days monthly in a patient with an established diagnosis of a headache disorder such as migraine or tension-type. Additionally, they must be&#x000a0;utilizing one or more symptomatic medications regularly (10 to 15 days per month, depending on the&#x000a0;type of drug consumed) for over three months. The headache characteristics are usually typical for their primary headache types, such as migraine or tension, although they are often more intense and frequent. Evolution towards MOH is substance-specific, occurring faster in those that overuse triptans, opiates, and combination analgesics&#x000a0;than those that overuse simple analgesics.</p>
        <p>The most common headache diagnoses before the evolution of MOH are migraines (65%), tension-type headaches (27%), and mixed/other headaches (8%).<xref ref-type="bibr" rid="article-17512.r30">[30]</xref>&#x000a0;Note that the transition from episodic to MOH is typically gradual in onset, with patients noting an increase in their headache intensity and frequency.&#x000a0;Patients typically describe their usual headache, but caution is advisable as features of their headache can change over time. Most patients with MOH (90%) utilize multiple different medications for relief.<xref ref-type="bibr" rid="article-17512.r30">[30]</xref>&#x000a0;Patients&#x000a0;often report morning headaches and neck pain resulting from overnight drug withdrawal or poor sleep quality.<xref ref-type="bibr" rid="article-17512.r31">[31]</xref></p>
        <p>The central sensitization caused by MOH can lead to skin hypersensitivity and the expansion of their&#x000a0;headache. Autonomic and gastrointestinal symptoms such as a runny nose, tearing, nausea, vomiting, and diarrhea can accompany their headache. Physical examination is typically nonfocal with no neurologic deficits. A false-positive diagnosis must be excluded by obtaining a detailed history and physical examination, including headache type, frequency, and drug use, to rule out any secondary headache syndromes that may require different management.</p>
      </sec>
      <sec id="article-17512.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Remember, it is the frequency of a headache and not the quality or intensity that makes the diagnosis of MOH. Unless there are concerning clinical features in the patient's history or physical examination,&#x000a0;there are no confirmatory nor necessary laboratory, radiographic or other tests required to diagnose MOH.</p>
        <p><bold>Diagnosis of Medication-overuse Headache (MOH) According to ICHD-3</bold>&#x000a0;M<bold>ust Meet Criteria A-C for the Diagnosis of MOH</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Headache on 15 or more days per month AND a pre-existing headache disorder</p>
          </list-item>
          <list-item>
            <p>Overuse of acute and/or symptomatic headache drugs for over three months&#x000a0;(Regular intake of drugs on greater than or equal to 10 days/month for ergotamines, triptans, opioids, and combination analgesics and on greater than or equal to 15 days per month for acetaminophen, ASA and NSAIDs)</p>
          </list-item>
          <list-item>
            <p>No better explanation by another ICHD-3 diagnosis&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Medication Overuse Headache by Drug Class</bold>&#x000a0;<bold>and Duration of Headache</bold><xref ref-type="bibr" rid="article-17512.r32">[32]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Ergotamine--&#x0003e;10 days/month for over 3 months</p>
          </list-item>
          <list-item>
            <p>Triptan--&#x0003e;10 days/month for over 3 months</p>
          </list-item>
          <list-item>
            <p>ASA--&#x0003e;15 days/month for over 3 months</p>
          </list-item>
          <list-item>
            <p>NSAIDs--&#x0003e;15 days/month for &#x0003e;3 months</p>
          </list-item>
          <list-item>
            <p>Acetaminophen/paracetamol--&#x0003e;15 days/month for over 3 months</p>
          </list-item>
          <list-item>
            <p>Opioids--&#x0003e;10 days/month for over 3 months</p>
          </list-item>
          <list-item>
            <p>Combination analgesics--&#x0003e;10 days/month for over 3 months</p>
          </list-item>
          <list-item>
            <p>Multiple drug classes--&#x0003e;10 days/month for over 3 months</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17512.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management approach includes patient education, effective prophylaxis, discontinuation of the overused analgesic, and follow-up to prevent a recurrence.</p>
        <p>
<bold>Prevention</bold>
</p>
        <p>MOH is felt to be a preventable disease; therefore, the emphasis should be on educating patients on the importance of appropriate medication administration and the risks not only of its side effects but also the potential development of chronic headaches with excessive medication use is essential.<xref ref-type="bibr" rid="article-17512.r33">[33]</xref>&#x000a0;Several small studies have emphasized the need for MOH patient education to reduce the incidents of MOH.<xref ref-type="bibr" rid="article-17512.r34">[34]</xref> About 75% of all the patients discontinued overused medication in one such study.<xref ref-type="bibr" rid="article-17512.r35">[35]</xref> The thinking is that only 8% of patients demonstrate knowledge that overuse of all types of headache medication, including those readily available over the counter, could lead to the development of MOH.</p>
        <p>Specific transitional strategies can be used to help discontinue the overused medication and hence reduce MOH.</p>
        <p><bold>Replacing the overused medication with an alternative symptomatic therapy:</bold> The overused magic medication is stopped, &#x000a0;preventive therapy is started or optimized, and alternative symptomatic medication is used for less than or equal to 2 days a week. This is particularly helpful for patients who have a higher risk of drug toxicity from overused medication than experiencing withdrawal symptoms. This approach is supported by evidence from open-labeled clinical trials.<xref ref-type="bibr" rid="article-17512.r36">[36]</xref> A guideline from the European Federation of Neurological Sciences recommends the abrupt discontinuation of the overused medication and if started prophylactic therapy initiation just before or at the time of drug discontinuation with close regular follow-up. If used, preventive therapies are started at low doses when MOH treatment begins, then titrated up with time with the choice of treatment depends upon previous drugs used, patient preferences, the type of primary headache disorder, comorbidities, and the side effect profile.<xref ref-type="bibr" rid="article-17512.r37">[37]</xref>&#x000a0;To date, therapy with beta-blockers, calcium channel blockers, tricyclic antidepressants, and anticonvulsants have all been utilized.<xref ref-type="bibr" rid="article-17512.r38">[38]</xref>&#x000a0;In studies, topiramate in studies was beneficial in patients with MOH but is more effective in patients with chronic migraine.<xref ref-type="bibr" rid="article-17512.r39">[39]</xref><xref ref-type="bibr" rid="article-17512.r40">[40]</xref>&#x000a0;In the PREEMPT trials for chronic migraines, onabotulinumtoxinA was studied. A number of the patients in the trial had MOH, and subgroup analysis performed on those patients reported benefit in reducing headache days, frequency, and severity but this study did not include patients who overused opioids.<xref ref-type="bibr" rid="article-17512.r41">[41]</xref><xref ref-type="bibr" rid="article-17512.r42">[42]</xref><xref ref-type="bibr" rid="article-17512.r43">[43]</xref>&#x000a0;The COMOESTAS&#x000a0;project demonstrated that the combination of detoxification and prophylaxis of MOH patients decreased disability, depression, and anxiety.<xref ref-type="bibr" rid="article-17512.r18">[18]</xref>&#x000a0;This group developed an evidence-based treatment protocol and at the end of their trial, 66% of MOH patients no longer overused medications and 47% reverted back to episodic headaches.<xref ref-type="bibr" rid="article-17512.r44">[44]</xref>&#x000a0;Not surprisingly when comparing inpatient versus outpatient programs, the dropout rate was higher in the outpatient setting.</p>
        <p><bold>Continuing overused medication during initial treatment:</bold> This approach is particularly beneficial for patients who are reluctant to stop the medication and are not at risk of toxicity.</p>
        <p><bold>Using bridge therapy (temporary medication):&#x000a0;</bold>A transitional therapy is advised for the patients with severe or frequent headaches and who are more likely to experience headaches while discontinuing the overused medication with start of symptomatic and preventive therapy.</p>
        <p>To help minimize a patient's withdrawal symptoms and maximize comfort during this phase several medication therapies have demonstrated usefulness.&#x000a0; Keep in mind that the offending drug should not be an option. Several NSAIDs have been trialed and demonstrated effective such as naproxen, indomethacin, and ketorolac.<xref ref-type="bibr" rid="article-17512.r45">[45]</xref><xref ref-type="bibr" rid="article-17512.r38">[38]</xref> Tizanidine is beneficial as an adjunct to NSAID therapy.<xref ref-type="bibr" rid="article-17512.r46">[46]</xref> Steroid therapy, in several currents studies, has demonstrated minimal to no effect on MOH withdrawal symptoms including fewer headache hours.<xref ref-type="bibr" rid="article-17512.r47">[47]</xref><xref ref-type="bibr" rid="article-17512.r48">[48]</xref><xref ref-type="bibr" rid="article-17512.r49">[49]</xref> Several antiemetics and neuroleptics have proven useful during this phase including prochlorperazine,&#x000a0;diphenhydramine, promethazine, metoclopramide, and chlorpromazine.<xref ref-type="bibr" rid="article-17512.r38">[38]</xref>&#x000a0;Infusions with dihydroergotamine (DHE) may be necessary in more complex cases.</p>
        <p>The "Raskin protocol" is one such regimen that compared intravenous DHE and metoclopramide every 8 hours versus diazepam in patients with MOH and it demonstrated that DHE was beneficial (89% headache free in 48 hours and 71% at 16 months) during the detoxification phase of MOH,&#x000a0;however it should not be utilized in patients with vascular disease.<xref ref-type="bibr" rid="article-17512.r31">[31]</xref>&#x000a0;Lidocaine infusions may be helpful in those with vascular disease.<xref ref-type="bibr" rid="article-17512.r50">[50]</xref>&#x000a0;A retrospective study by Williams demonstrated 90% of MOH patients with a history of analgesic abuse including opioids had headache improvement, 97% withdrew the overused drug, and 70% had sustained benefits at 6 months. Valproate showed improvement in 80% of patients with MOH in a small study with good patient tolerance.<xref ref-type="bibr" rid="article-17512.r51">[51]</xref>&#x000a0;Intravenous hydration, antiemetics, NSAIDs, and magnesium are also helpful during the withdrawal phase.<xref ref-type="bibr" rid="article-17512.r52">[52]</xref></p>
        <p><bold>Discontinuing the overused medication before starting prophylactic therapy:</bold> &#x000a0;And alternative strategy includes stopping the overused medication for two months prior to the start of preventive medication. &#x000a0;However, patients may not tolerate this approach. Therefore, &#x000a0;this route is usually not advised.</p>
        <p>
<bold>Treatment approach based on discontinuation of the specific offending drug:</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Discontinuation of the drugs other than opioids, barbiturates, or benzodiazepines:
<list list-type="order"><list-item><p>Start or optimize preventive therapy</p></list-item><list-item><p>Switch from overused medication to an alternative medication from a different class. The use of acute medication should be limited don&#x02019;t know more than two days per week.OR Slowly taper the acute medication as the frequency of headaches decreases in response to preventive therapy. However, for patients who still experience headaches, bridge therapy with a long acting NSAID or steroid should be added.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Discontinuation of opioids, barbiturates, or benzodiazepines: Drugs are gradually tapered (in 2-4 weeks) if used at higher dosages. However, they may be withdrawn abruptly if lesser dosages are taken.
<list list-type="order"><list-item><p>Treatment with once a week transdermal clonidine patch (0.1 to 0.2 mg/24 hours) may be advised for one to two weeks to manage opioid withdrawal symptoms.</p></list-item><list-item><p>Phenobarbital is particularly recommended for patients discontinuing butalbital. A 30 mg of phenobarbital is equivalent to 100 mg of butalbital. Therefore, it corresponds with maximum dose of 90 mg of phenobarbitol with 300 mg of butabital.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17512.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of MOH would include any form of chronic daily headache, whether it is a primary or secondary headache diagnosis, including migraine, tension-type headache, cluster headache,&#x000a0;short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), hypnic headache, nummular headache, and chronic paroxysmal hemicrania. Always ask patients about a history of head trauma, and if a patient&#x02019;s history or physical examination causes concern, then appropriate diagnostic testing should be performed to rule out the possibility of a severe medical or neurologic condition. Some differentials that should be under consideration are venous sinus thrombosis, subdural hematoma, carbon monoxide poisoning, brain tumors, hydrocephalus, and idiopathic intracranial hypertension.</p>
      </sec>
      <sec id="article-17512.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Overuse of acute therapy can lead to a poor prognosis of chronic headache and lower quality of life by itself.<xref ref-type="bibr" rid="article-17512.r53">[53]</xref>&#x000a0;The key to MOH treatment is patient motivation.<xref ref-type="bibr" rid="article-17512.r38">[38]</xref>&#x000a0;Outcomes for MOH patients withdrawing from acute drug overuse have had reports in multiple studies with a generally&#x000a0;accepted success rate of greater than 50% reduction from baseline headache frequency. Rates of successful withdrawal have been reported in around 50 to 70% of MOH patients after 1 year.<xref ref-type="bibr" rid="article-17512.r54">[54]</xref>&#x000a0;A good predictor of long-term success is retaining withdrawal after 1 year.<xref ref-type="bibr" rid="article-17512.r55">[55]</xref><xref ref-type="bibr" rid="article-17512.r56">[56]</xref>&#x000a0;Relapse rates after 6 years range between 40 to 50%.<xref ref-type="bibr" rid="article-17512.r57">[57]</xref>&#x000a0;A successful withdrawal phase leads to a better response for prophylactic treatment even in those patients with little to no improvement in headache&#x000a0;frequency.<xref ref-type="bibr" rid="article-17512.r58">[58]</xref>&#x000a0;Several predictors for relapse have been documented such as tension-type headache, longer duration of regular intake, a high number of acute treatments, no improvement after 2 months of withdrawal, smoking, and alcohol use, and return to overused drugs.<xref ref-type="bibr" rid="article-17512.r59">[59]</xref><xref ref-type="bibr" rid="article-17512.r60">[60]</xref><xref ref-type="bibr" rid="article-17512.r61">[61]</xref>&#x000a0;Triptan overuse has a lower relapse rate while combined drug therapy has a higher relapse rate.<xref ref-type="bibr" rid="article-17512.r62">[62]</xref>&#x000a0;Finally, codeine-containing drugs&#x000a0;and patient-reported poor sleep quality, and high body pain are probable predictors for poor 1-year outcomes.<xref ref-type="bibr" rid="article-17512.r63">[63]</xref> Adding behavioral therapy to the treatment algorithm can greatly reduce the relapse rates for MOH. In this particular study, 42% of patients had a relapse of headache&#x000a0;at 3 years, but only 12.5% reverted when coupled with behavioral therapy.<xref ref-type="bibr" rid="article-17512.r64">[64]</xref></p>
      </sec>
      <sec id="article-17512.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Side effects from the medication, including dependence and toxicity. Use of NSAIDs can cause upper gastrointestinal bleeding.</p>
      </sec>
      <sec id="article-17512.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients are initially managed by internists and general physicians. Neurology and or psychiatry consultations can be sought when necessary.</p>
      </sec>
      <sec id="article-17512.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with MOH will fair better if their comorbidities such as mood disorders, obesity, smoking, or inactivity are also addressed, and continual support is offered in the form of education, patient monitoring, and behavioral therapies.&#x000a0;MOH awareness in the general public should be a goal, as a study from 2014 demonstrated that 77% of undergraduate students were not aware of the existence of MOH, and after learning about MOH, 83% of the students felt there should be warnings about MOH on medication bottles and 80% after learning about MOH would reduce analgesic consumption.<xref ref-type="bibr" rid="article-17512.r65">[65]</xref></p>
      </sec>
      <sec id="article-17512.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>MOH is a common and worldwide problem with a prevalence of 1% in the general population but accounts for approximately 11 to 70% of those with chronic daily headaches. Often under-recognized and unfortunately correlate with a significant negative impact on the patient's quality of life. That opiates and combination analgesics&#x000a0;carry an increased risk for MOH needs to be recognized. Among the multiple risk factors for the development of MOH, some are modifiable and require attention and action. Anxiety and depression are common comorbidities, and up to 50% of patients show dependence-type behaviors like tolerance or inability to control pain medication utilization.&#x000a0;</p>
        <p>Treatment trials are still needed to determine the best evidence-based approach for helping these patients break their vicious headache cycle, but intervention will require patient counseling, detoxification, and prevention therapy. The future needs to include a focus on increased awareness of MOH for the general population and primary prevention strategies for patients and providers.&#x000a0; To achieve treatment success, it is essential that the primary care provider, nurse practitioner, pharmacist, and internist openly communicate with the neurologist when MOH is suspected.</p>
      </sec>
      <sec id="article-17512.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17512&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17512">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/migraine-headaches/medication-overuse-headache/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17512">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17512/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17512">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17512.s16">
        <title>References</title>
        <ref id="article-17512.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vandenbussche</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laterza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lisicki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lupi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tischler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Toom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vandervorst</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Quintana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paemeleire</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Medication-overuse headache: a widely recognized entity amidst ongoing debate.</article-title>
            <source>J Headache Pain</source>
            <year>2018</year>
            <month>Jul</month>
            <day>13</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">30003412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkinson</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Heine</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Opiate use to control bowel motility may induce chronic daily headache in patients with migraine.</article-title>
            <source>Headache</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>303</fpage>
            <page-range>303-9</page-range>
            <pub-id pub-id-type="pmid">11264692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boes</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Capobianco</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Chronic migraine and medication-overuse headache through the ages.</article-title>
            <source>Cephalalgia</source>
            <year>2005</year>
            <month>May</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>378</fpage>
            <page-range>378-90</page-range>
            <pub-id pub-id-type="pmid">15839853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathew</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Reuveni</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Transformed or evolutive migraine.</article-title>
            <source>Headache</source>
            <year>1987</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-6</page-range>
            <pub-id pub-id-type="pmid">3570762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <article-title>Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.</article-title>
            <source>Cephalalgia</source>
            <year>1988</year>
            <volume>8 Suppl 7</volume>
            <fpage>1</fpage>
            <page-range>1-96</page-range>
            <pub-id pub-id-type="pmid">3048700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <collab>Headache Classification Subcommittee of the International Headache Society</collab>
            <article-title>The International Classification of Headache Disorders: 2nd edition.</article-title>
            <source>Cephalalgia</source>
            <year>2004</year>
            <volume>24 Suppl 1</volume>
            <fpage>9</fpage>
            <page-range>9-160</page-range>
            <pub-id pub-id-type="pmid">14979299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <article-title>Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-211</page-range>
            <pub-id pub-id-type="pmid">29368949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Runken</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.</article-title>
            <source>Headache</source>
            <year>2013</year>
            <season>Nov-Dec</season>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>1548</fpage>
            <page-range>1548-63</page-range>
            <pub-id pub-id-type="pmid">23992516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shahbeigi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fereshtehnejad</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Golmakani</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Tadayyon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jalilzadeh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pakdaman</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of headaches in Tehran urban area: a population-based cross-sectional study in district 8, year 2010.</article-title>
            <source>Neurol Sci</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>1157</fpage>
            <page-range>1157-66</page-range>
            <pub-id pub-id-type="pmid">23010877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <collab>GBD 2016 Risk Factors Collaborators</collab>
            <article-title>Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Sep</month>
            <day>16</day>
            <volume>390</volume>
            <issue>10100</issue>
            <fpage>1345</fpage>
            <page-range>1345-1422</page-range>
            <pub-id pub-id-type="pmid">28919119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Stovner</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Zwart</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Tr&#x000f8;ndelag Health Studies.</article-title>
            <source>Pain</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>153</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-61</page-range>
            <pub-id pub-id-type="pmid">22018971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scher</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Bigal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study.</article-title>
            <source>Cephalalgia</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>321</fpage>
            <page-range>321-8</page-range>
            <pub-id pub-id-type="pmid">19614708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Metabolic syndrome in female migraine patients is associated with medication overuse headache: a clinic-based study in China.</article-title>
            <source>Eur J Neurol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>1228</fpage>
            <page-range>1228-34</page-range>
            <pub-id pub-id-type="pmid">25981360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radat</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lanteri-Minet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>What is the role of dependence-related behavior in medication-overuse headache?</article-title>
            <source>Headache</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>10</issue>
            <fpage>1597</fpage>
            <page-range>1597-611</page-range>
            <pub-id pub-id-type="pmid">20807250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shand</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Goicochea</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Valenzuela</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fadic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tassorelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>G</given-names>
              </name>
              <collab>COMOESTAS CONSORTIUM</collab>
            </person-group>
            <article-title>Clinical and Demographical Characteristics of Patients with Medication Overuse Headache in Argentina and Chile: Analysis of the Latin American Section of COMOESTAS Project.</article-title>
            <source>J Headache Pain</source>
            <year>2015</year>
            <volume>16</volume>
            <fpage>83</fpage>
            <pub-id pub-id-type="pmid">26382855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cevoli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sancisi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grimaldi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pierangeli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zanigni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nicodemo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Family history for chronic headache and drug overuse as a risk factor for headache chronification.</article-title>
            <source>Headache</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>412</fpage>
            <page-range>412-8</page-range>
            <pub-id pub-id-type="pmid">19267785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarchielli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Corbelli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cupini</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bernardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bono</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Piero</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Petolicchio</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Livrea</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Prudenzano</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Pini</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Sandrini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Allena</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caproni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beghi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calabresi</surname>
                <given-names>P</given-names>
              </name>
              <collab>SAMOHA Study Group</collab>
            </person-group>
            <article-title>Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study.</article-title>
            <source>Eur J Neurol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-91</page-range>
            <pub-id pub-id-type="pmid">26228376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bendtsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Munksgaard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tassorelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lainez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fadic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spadafora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stoppini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>R</given-names>
              </name>
              <collab>COMOESTAS Consortium</collab>
            </person-group>
            <article-title>Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project).</article-title>
            <source>Cephalalgia</source>
            <year>2014</year>
            <month>May</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>426</fpage>
            <page-range>426-33</page-range>
            <pub-id pub-id-type="pmid">24322480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Rolan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment.</article-title>
            <source>Cephalalgia</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-64</page-range>
            <pub-id pub-id-type="pmid">23144180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woolf</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Central sensitization: implications for the diagnosis and treatment of pain.</article-title>
            <source>Pain</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>152</volume>
            <issue>3 Suppl</issue>
            <fpage>S2</fpage>
            <page-range>S2-S15</page-range>
            <pub-id pub-id-type="pmid">20961685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Medication Overuse Headache: Pathophysiological Insights from Structural and Functional Brain MRI Research.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>57</volume>
            <issue>7</issue>
            <fpage>1173</fpage>
            <page-range>1173-1178</page-range>
            <pub-id pub-id-type="pmid">28160280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Neuroimaging Findings in Patients with Medication Overuse Headache.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Jan</month>
            <day>16</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">29340793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srikiatkhachorn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarasub</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Govitrapong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache.</article-title>
            <source>Headache</source>
            <year>2000</year>
            <month>May</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>343</fpage>
            <page-range>343-50</page-range>
            <pub-id pub-id-type="pmid">10849027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Lorenzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Curr&#x000e0;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grieco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santorelli</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Lepre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Porretta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pascale</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pierelli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Cortical response to somatosensory stimulation in medication overuse headache patients is influenced by angiotensin converting enzyme (ACE) I/D genetic polymorphism.</article-title>
            <source>Cephalalgia</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>16</issue>
            <fpage>1189</fpage>
            <page-range>1189-97</page-range>
            <pub-id pub-id-type="pmid">23053304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Binder</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Scharfman</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Brain-derived neurotrophic factor.</article-title>
            <source>Growth Factors</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>123</fpage>
            <page-range>123-31</page-range>
            <pub-id pub-id-type="pmid">15518235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skorpen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Variation in the COMT gene: implications for pain perception and pain treatment.</article-title>
            <source>Pharmacogenomics</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>669</fpage>
            <page-range>669-84</page-range>
            <pub-id pub-id-type="pmid">19374521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serretti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mandelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Ronchi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Serotonin transporter gene variants and behavior: a comprehensive review.</article-title>
            <source>Curr Drug Targets</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>1659</fpage>
            <page-range>1659-69</page-range>
            <pub-id pub-id-type="pmid">17168841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Felice</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ossipov</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chichorro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Vanderah</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Dussor</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Porreca</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Triptan-induced latent sensitization: a possible basis for medication overuse headache.</article-title>
            <source>Ann Neurol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-37</page-range>
            <pub-id pub-id-type="pmid">20373344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coppola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Curr&#x000e0;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Lorenzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gorini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sava</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pierelli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Abnormal cortical responses to somatosensory stimulation in medication-overuse headache.</article-title>
            <source>BMC Neurol</source>
            <year>2010</year>
            <month>Dec</month>
            <day>30</day>
            <volume>10</volume>
            <fpage>126</fpage>
            <pub-id pub-id-type="pmid">21192822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Da Silva</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Lake</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Clinical aspects of medication overuse headaches.</article-title>
            <source>Headache</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>211</fpage>
            <page-range>211-7</page-range>
            <pub-id pub-id-type="pmid">24116964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tepper</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Medication Overuse Headache.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>845</fpage>
            <page-range>845-846</page-range>
            <pub-id pub-id-type="pmid">28444948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <collab>Headache Classification Committee of the International Headache Society (IHS)</collab>
            <article-title>The International Classification of Headache Disorders, 3rd edition (beta version).</article-title>
            <source>Cephalalgia</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>629</fpage>
            <page-range>629-808</page-range>
            <pub-id pub-id-type="pmid">23771276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapoport</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Medication overuse headache: awareness, detection and treatment.</article-title>
            <source>CNS Drugs</source>
            <year>2008</year>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>995</fpage>
            <page-range>995-1004</page-range>
            <pub-id pub-id-type="pmid">18998738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lagman-Bartolome</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lawler</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lay</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Headache Education Active-Waiting Directive: A Program to Enhance Well-Being During Long Referral Wait Times.</article-title>
            <source>Headache</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-117</page-range>
            <pub-id pub-id-type="pmid">29131328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Di Lorenzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Faroni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cesarino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs.</article-title>
            <source>Cephalalgia</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>1097</fpage>
            <page-range>1097-105</page-range>
            <pub-id pub-id-type="pmid">16919060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hentz</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Sahai-Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murinova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Spare</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Treppendahl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Birlea</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Digre</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <collab>MOTS Investigators</collab>
            </person-group>
            <article-title>Patient-Centered Treatment of Chronic Migraine With Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial.</article-title>
            <source>Neurology</source>
            <year>2022</year>
            <month>Apr</month>
            <day>05</day>
            <volume>98</volume>
            <issue>14</issue>
            <fpage>e1409</fpage>
            <page-range>e1409-e1421</page-range>
            <pub-id pub-id-type="pmid">35169011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Amoozegar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dilli</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Medication overuse headache.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>509</fpage>
            <pub-id pub-id-type="pmid">25398377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saper</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Da Silva</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Medication overuse headache: history, features, prevention and management strategies.</article-title>
            <source>CNS Drugs</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>867</fpage>
            <page-range>867-77</page-range>
            <pub-id pub-id-type="pmid">23925669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Bigal</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bussone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ascher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hulihan</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Biondi</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse.</article-title>
            <source>Cephalalgia</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>1021</fpage>
            <page-range>1021-7</page-range>
            <pub-id pub-id-type="pmid">19735529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russell</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Lundqvist</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prevention and management of medication overuse headache.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>290</fpage>
            <page-range>290-5</page-range>
            <pub-id pub-id-type="pmid">22547100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Turkel</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>DeGryse</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Brin</surname>
                <given-names>MF</given-names>
              </name>
              <collab>PREEMPT 1 Chronic Migraine Study Group</collab>
            </person-group>
            <article-title>OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.</article-title>
            <source>Cephalalgia</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>7</issue>
            <fpage>793</fpage>
            <page-range>793-803</page-range>
            <pub-id pub-id-type="pmid">20647170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Turkel</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>DeGryse</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Brin</surname>
                <given-names>MF</given-names>
              </name>
              <collab>PREEMPT 2 Chronic Migraine Study Group</collab>
            </person-group>
            <article-title>OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.</article-title>
            <source>Cephalalgia</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>7</issue>
            <fpage>804</fpage>
            <page-range>804-14</page-range>
            <pub-id pub-id-type="pmid">20647171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Blumenfeld</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cady</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Sirimanne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeGryse</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Turkel</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.</article-title>
            <source>J Neurol Sci</source>
            <year>2013</year>
            <month>Aug</month>
            <day>15</day>
            <volume>331</volume>
            <issue>1-2</issue>
            <fpage>48</fpage>
            <page-range>48-56</page-range>
            <pub-id pub-id-type="pmid">23790235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tassorelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Allena</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Icco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sances</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lainez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fadic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spadafora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>G</given-names>
              </name>
              <collab>the COMOESTAS Consortium</collab>
            </person-group>
            <article-title>A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study.</article-title>
            <source>Cephalalgia</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>645</fpage>
            <page-range>645-655</page-range>
            <pub-id pub-id-type="pmid">24558185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berciano</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Daily chronic headache in patients with migraine induced by abuse of ergotamine-analgesics: response due to a protocol of outpatient treatment].</article-title>
            <source>Neurologia</source>
            <year>1993</year>
            <season>Aug-Sep</season>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>212</fpage>
            <page-range>212-5</page-range>
            <pub-id pub-id-type="pmid">8104438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache.</article-title>
            <source>Headache</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-7</page-range>
            <pub-id pub-id-type="pmid">11903539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pageler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gaul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lampl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kraya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Foerderreuther</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study.</article-title>
            <source>Cephalalgia</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>202</fpage>
            <page-range>202-7</page-range>
            <pub-id pub-id-type="pmid">23093541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f8;e</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Mygland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvesen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prednisolone does not reduce withdrawal headache: a randomized, double-blind study.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>Jul</month>
            <day>03</day>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-31</page-range>
            <pub-id pub-id-type="pmid">17475943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pageler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Limmroth</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Prednisone vs. placebo in withdrawal therapy following medication overuse headache.</article-title>
            <source>Cephalalgia</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-6</page-range>
            <pub-id pub-id-type="pmid">18039339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse.</article-title>
            <source>Cephalalgia</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>963</fpage>
            <page-range>963-71</page-range>
            <pub-id pub-id-type="pmid">14984229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Karpitskiy</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Intravenous valproate sodium in the treatment of daily headache.</article-title>
            <source>Headache</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>519</fpage>
            <page-range>519-22</page-range>
            <pub-id pub-id-type="pmid">12167141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trucco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meineri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gionco</surname>
                <given-names>M</given-names>
              </name>
              <collab>Gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee (Neurological Hospital Interregional Group for the Study of Headaches)</collab>
            </person-group>
            <article-title>Medication overuse headache: withdrawal and prophylactic therapeutic regimen.</article-title>
            <source>Headache</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>989</fpage>
            <page-range>989-97</page-range>
            <pub-id pub-id-type="pmid">20236349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Probyn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mistry</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Underwood</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matharu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pincus</surname>
                <given-names>T</given-names>
              </name>
              <collab>CHESS Team</collab>
            </person-group>
            <article-title>Prognostic factors for chronic headache: A systematic review.</article-title>
            <source>Neurology</source>
            <year>2017</year>
            <month>Jul</month>
            <day>18</day>
            <volume>89</volume>
            <issue>3</issue>
            <fpage>291</fpage>
            <page-range>291-301</page-range>
            <pub-id pub-id-type="pmid">28615422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>B&#x000f8;e</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Stovner</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Medication overuse headache: a critical review of end points in recent follow-up studies.</article-title>
            <source>J Headache Pain</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>373</fpage>
            <page-range>373-7</page-range>
            <pub-id pub-id-type="pmid">20473701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f8;e</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Thortveit</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vatne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mygland</surname>
                <given-names>&#x000c5;</given-names>
              </name>
            </person-group>
            <article-title>Chronic headache with medication overuse: Long-term prognosis after withdrawal therapy.</article-title>
            <source>Cephalalgia</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>13</issue>
            <fpage>1215</fpage>
            <page-range>1215-1221</page-range>
            <pub-id pub-id-type="pmid">27707950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zidverc-Trajkovic</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pekmezovic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jovanovic</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Pavlovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mijajlovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radojicic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sternic</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Long-term predictors of remission in patients treated for medication-overuse headache at a specialized headache center: A prospective cohort study.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>265</fpage>
            <page-range>265-273</page-range>
            <pub-id pub-id-type="pmid">27940881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Muessig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dzagnidze</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fritsche</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Limmroth</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Medication overuse headache: rates and predictors for relapse in a 4-year prospective study.</article-title>
            <source>Cephalalgia</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-5</page-range>
            <pub-id pub-id-type="pmid">15606564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeeberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Olesen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness.</article-title>
            <source>Cephalalgia</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>1192</fpage>
            <page-range>1192-8</page-range>
            <pub-id pub-id-type="pmid">16961785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pini</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Cicero</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Sandrini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of patients treated for chronic headache with analgesic overuse.</article-title>
            <source>Cephalalgia</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>878</fpage>
            <page-range>878-83</page-range>
            <pub-id pub-id-type="pmid">11903281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Krabbe</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ergotamine abuse. Do patients benefit from withdrawal?</article-title>
            <source>Cephalalgia</source>
            <year>1981</year>
            <month>Mar</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-32</page-range>
            <pub-id pub-id-type="pmid">15645831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sances</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ghiotto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guaschino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rezzani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guidetti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Risk factors in medication-overuse headache: a 1-year follow-up study (care II protocol).</article-title>
            <source>Cephalalgia</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>329</fpage>
            <page-range>329-36</page-range>
            <pub-id pub-id-type="pmid">19614697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suhr</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gralow</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Grotemeyer</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Husstedt</surname>
                <given-names>IW</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced headache: long-term results of stationary versus ambulatory withdrawal therapy.</article-title>
            <source>Cephalalgia</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-9</page-range>
            <pub-id pub-id-type="pmid">10099859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f8;e</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Salvesen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mygland</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy.</article-title>
            <source>Eur J Neurol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>705</fpage>
            <page-range>705-12</page-range>
            <pub-id pub-id-type="pmid">19236455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grazzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Andrasik</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Usai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kass</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bussone</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years.</article-title>
            <source>Headache</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>483</fpage>
            <page-range>483-90</page-range>
            <pub-id pub-id-type="pmid">12167136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17512.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Dereix</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Ganepola</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Nightingale</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Markey</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Aveyard</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Should we educate about the risks of medication overuse headache?</article-title>
            <source>J Headache Pain</source>
            <year>2014</year>
            <month>Feb</month>
            <day>13</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">24524380</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
